BR9914631A - Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades - Google Patents

Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades

Info

Publication number
BR9914631A
BR9914631A BR9914631-2A BR9914631A BR9914631A BR 9914631 A BR9914631 A BR 9914631A BR 9914631 A BR9914631 A BR 9914631A BR 9914631 A BR9914631 A BR 9914631A
Authority
BR
Brazil
Prior art keywords
treatment
disease prevention
tolerance
low density
prevention
Prior art date
Application number
BR9914631-2A
Other languages
English (en)
Inventor
Yehuda Shoenfeld
Jacob George
Dror Harats
Original Assignee
Cardimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardimmune Ltd filed Critical Cardimmune Ltd
Publication of BR9914631A publication Critical patent/BR9914631A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"COMPOSIçãO IMONOLóGICA ORAL INDUTORA DE TOLERâNCIA PARA PREVENçãO E/OU TRATAMENTO DE ENFERMIDADES E MéTODO PARA PREVENçãO E/OU TRATAMENTO DE ENFERMIDADES", compreendendo um componente ativo selecionado dentre o grupo consistente de lipoproteína modificada de baixa densidade, lipoproteína oxidada de baixa densidade (Ox LDL), proteína de choque térmico 60/65 (HSP 60/65), beta~ 2~-glicoproteína-1 (<225>~ 2~-GP-1), derivados funcionais e misturas das mesmas, em combinação com um veículo farmaceuticamente aceitável para administração oral.
BR9914631-2A 1998-10-04 1999-09-30 Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades BR9914631A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12644798A IL126447A (en) 1998-10-04 1998-10-04 An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
PCT/IL1999/000519 WO2000020019A2 (en) 1998-10-04 1999-09-30 A composition for the prevention and/or treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
BR9914631A true BR9914631A (pt) 2001-07-03

Family

ID=11072009

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914631-2A BR9914631A (pt) 1998-10-04 1999-09-30 Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades

Country Status (17)

Country Link
US (2) US20030114367A1 (pt)
EP (1) EP1126867B1 (pt)
JP (1) JP4834219B2 (pt)
KR (1) KR100680707B1 (pt)
CN (2) CN100430090C (pt)
AT (1) ATE240115T1 (pt)
AU (1) AU760582B2 (pt)
BR (1) BR9914631A (pt)
CA (1) CA2345445C (pt)
DE (1) DE69907945T2 (pt)
DK (1) DK1126867T3 (pt)
ES (1) ES2198163T3 (pt)
HK (2) HK1076600A1 (pt)
HU (1) HUP0104410A3 (pt)
IL (1) IL126447A (pt)
PT (1) PT1126867E (pt)
WO (1) WO2000020019A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
JP4789311B2 (ja) * 1999-07-16 2011-10-12 エンゾー セラピューティクス， インコーポレイテッド 新規の選択的免疫ダウンレギュレーション（ｓｉｄｒ）媒介性移植プロセス、被験体における疾患を予防または処置するためのプロセス、およびｓｉｄｒを確立するために有用である、馴化またはプログラミングされた細胞、組織または器官を含む組成物
CA2394504A1 (en) * 1999-12-15 2001-06-21 Peptor Ltd. Fragments and antagonists of heat shock protein 60
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
FR2816060A1 (fr) * 2000-10-27 2002-05-03 Pf Medicament Procede d'identification de nouvelles molecules se liant au recepteur lox et utilisation de ces molecules
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
JP4191997B2 (ja) * 2001-01-04 2008-12-03 ヴァスキュラー バイオジェニックス リミテッド アテローム性動脈硬化を防止および処置するために斑関連分子を用いる方法および斑関連分子を含有する組成物
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20030077279A1 (en) * 2001-10-24 2003-04-24 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting toll-like receptor-4
WO2003099833A2 (en) * 2002-05-17 2003-12-04 Board Of Regents, The University Of Texas System Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
US7264813B2 (en) * 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
EP1676602A1 (en) * 2005-01-04 2006-07-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Continuous administration of epitopes derived from protein present in atherosclerotic plaque for the treatment of atherosclerosis
AU2006206187B2 (en) * 2005-01-24 2011-03-10 Board Of Regents, The University Of Texas System Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
BRPI0618569A2 (pt) * 2005-11-14 2011-09-06 Nestec Sa promoção de toleráncia oral com proteìnas glicadas
US8961982B2 (en) * 2005-12-16 2015-02-24 The Regents Of The University Of California Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
JP5654446B2 (ja) * 2008-04-10 2015-01-14 ザ・トロンボシス・リサーチ・インスティテュートＴｈｅ Ｔｈｒｏｍｂｏｓｉｓ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗アテロームワクチン
EP2328911A4 (en) 2008-09-22 2012-03-14 Cedars Sinai Medical Center HUMAN MD-2 IN SHORT FORM AS NEGATIVE REGULATOR OF TOLL-4 TYPE RECEIVER SIGNALING
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
CN103185801B (zh) * 2011-12-30 2015-04-15 深圳市亚辉龙生物科技有限公司 一种检测抗β2糖蛋白I抗体的试剂装置及其方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) * 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3993073A (en) * 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3948262A (en) * 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3699963A (en) * 1969-10-31 1972-10-24 Alza Corp Therapeutic adhesive patch
US3703173A (en) * 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US3944064A (en) * 1973-10-26 1976-03-16 Alza Corporation Self-monitored device for releasing agent at functional rate
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4624251A (en) * 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
JPS61130238A (ja) * 1984-11-30 1986-06-18 Res Dev Corp Of Japan 動脈硬化巣認識モノクロナル抗体および反応試薬
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4690683A (en) * 1985-07-02 1987-09-01 Rutgers, The State University Of New Jersey Transdermal varapamil delivery device
US6019970A (en) * 1985-07-31 2000-02-01 Ghent William R. Treatment of iodine deficiency diseases
HU207452B (en) * 1986-03-21 1993-04-28 Eurasiam Lab Method for producing therapeutical preparations containing active ingredient having biologicallu active protein structure
US6025477A (en) * 1986-03-31 2000-02-15 Calenoff; Emanuel Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
ATE71287T1 (de) * 1986-06-13 1992-01-15 Alza Corp Aktivierung eines transdermalen drogenabgabesystems durch feuchtigkeit.
CN1093255A (zh) * 1986-06-17 1994-10-12 恩特雷麦德有限公司 抗甾醇疫苗
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US6645504B1 (en) * 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US4917895A (en) * 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US4837027A (en) * 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
DK0482089T3 (da) * 1989-07-14 1998-05-25 Autoimmune Inc Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker
WO1991006006A1 (fr) * 1989-10-19 1991-05-02 Yamasa Shoyu Kabushiki Kaisha Excipient de liaison d'anticorps antiphospholipides, immuno-analyse utilisant cet excipient et kit associe
US5196324A (en) * 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
JPH04506415A (ja) * 1990-04-06 1992-11-05 ヤマサ醤油株式会社 リン脂質およびその抗体の測定方法
CA2058769C (en) * 1990-04-06 1999-03-02 Steven Anthony Krilis Methods for determining phospholipids and antibodies thereof
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
ES2109362T3 (es) * 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
CA2107557C (en) * 1992-02-05 1999-07-20 Eiji Matsuura Solid phase reagent and assay method for antibody using the same
US6130059A (en) * 1992-03-02 2000-10-10 Covacci; Antonello Helicobacter pylori proteins useful for vaccines and diagnostics
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5409710A (en) * 1993-04-20 1995-04-25 Endocon, Inc. Foam cell drug delivery
JP3370334B2 (ja) * 1993-09-29 2003-01-27 栄次 松浦 酸化リポタンパク質の測定法およびその用途
WO1995010045A1 (de) * 1993-10-01 1995-04-13 Siemens Aktiengesellschaft Verfahren und anordnung zum messen eines elektrischen stromes mit zwei gegenläufigen lichtsignalen unter ausnutzung des faraday-effekts
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
AU696638B2 (en) * 1993-11-16 1998-09-17 Yamasa Corporation Method of assaying antiphospholipid antibody and kit therefor
ATE260295T1 (de) * 1994-03-21 2004-03-15 Univ Utrecht Peptidfragmente von mikrobiellen stressproteinen und daraus hergestellte pharmazeutische zusammensetzungen für die behandlung und vorbeugung von entzündungserkrankungen
DE4413938A1 (de) * 1994-04-21 1995-11-02 Gerhild Dr Wildner Peptide als Therapeutikum für Autoimmunerkrankungen
US6156500A (en) * 1995-02-10 2000-12-05 Millennium Pharmaceuticals, Inc. Methods for the treatment and diagnosis of cardiovascular disease
US6410775B1 (en) * 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
AU6333796A (en) * 1995-06-07 1996-12-30 Autoimmune, Inc. Oral tolerance in skin diseases presenting with t-cell media ted inflammation
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
TW460753B (en) * 1995-07-20 2001-10-21 Shinetsu Chemical Co Chemically amplified positive resist material
FR2742989B1 (fr) * 1995-12-29 1998-01-23 Adir Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6114395A (en) * 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
US6225070B1 (en) * 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US6019975A (en) * 1997-11-13 2000-02-01 Elizabeth Arden Co., Division Of Conopco, Inc. Antisebum and antioxidant compositions containing a low molecular weight fraction of gugulipid
US5935577A (en) * 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US5945308A (en) * 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
BR9912053A (pt) * 1998-07-13 2001-04-03 Univ Texas Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US20050148499A1 (en) * 1998-10-04 2005-07-07 Dror Harats Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of atherosclerosis
US6812205B2 (en) * 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
JP4191997B2 (ja) * 2001-01-04 2008-12-03 ヴァスキュラー バイオジェニックス リミテッド アテローム性動脈硬化を防止および処置するために斑関連分子を用いる方法および斑関連分子を含有する組成物
WO2002070523A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
US20030100036A1 (en) * 2001-11-08 2003-05-29 Aristo Vojdani Saliva immunoassay for detection of antibodies for cardiovascular disease

Also Published As

Publication number Publication date
CA2345445C (en) 2010-08-24
WO2000020019A3 (en) 2000-06-09
HK1043743A1 (en) 2002-09-27
KR100680707B1 (ko) 2007-02-08
US20030114367A1 (en) 2003-06-19
ES2198163T3 (es) 2004-01-16
CN1332636A (zh) 2002-01-23
CN100430090C (zh) 2008-11-05
HUP0104410A3 (en) 2004-07-28
AU5996699A (en) 2000-04-26
KR20010083886A (ko) 2001-09-03
IL126447A0 (en) 1999-08-17
AU760582B2 (en) 2003-05-15
US20020025321A1 (en) 2002-02-28
EP1126867B1 (en) 2003-05-14
JP2002526416A (ja) 2002-08-20
IL126447A (en) 2004-09-27
HK1076600A1 (en) 2006-01-20
CA2345445A1 (en) 2000-04-13
DE69907945D1 (de) 2003-06-18
PT1126867E (pt) 2003-09-30
WO2000020019A2 (en) 2000-04-13
DE69907945T2 (de) 2004-03-11
CN1616085A (zh) 2005-05-18
ATE240115T1 (de) 2003-05-15
DK1126867T3 (da) 2003-09-08
JP4834219B2 (ja) 2011-12-14
HUP0104410A2 (hu) 2002-03-28
CN1176716C (zh) 2004-11-24
EP1126867A2 (en) 2001-08-29

Similar Documents

Publication Publication Date Title
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
BR9814923A (pt) Método para tratamento de doença de alzheimer
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
IL112664A0 (en) 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
BR0110420A (pt) Agonistas muscarìnicos
IL112667A0 (en) 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
BR9815255A (pt) Toxina de botulismo modificada, vacina oralcontra o botulismo, vacina oral contra umantìgeno selecionado e método para ministraroralmente um agente terapêutico a um animal
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
BR9811094A (pt) Agente terapêutico para tumores linfáticos
PT998287E (pt) Utilizacao de levobupivacaina
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
EE04493B1 (et) Tsüklopenteeni derivaadid, neid sisaldav farmatseutiline kompositsioon ning ühendite kasutamine ravimina inimestel esinevate motiliini retseptoriga seotud häirete raviks
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
KR970061248A (ko) 알츠하이머병 치료용 1, 1, 2-트리페닐부트-1-엔 유도체
AU3733295A (en) Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
IL112668A0 (en) 4-amino 6-substituted mycophenolic acid and derivatives thereof, their preparation and pharmaceutical compositions containing them
BR0005319A (pt) Tratamento combinado para depressão e ansiedade

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 E 37 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.